Arcadia Biosciences (RKDA) 10-Q 13 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 11, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		10,832,203
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Small Business	true
Extended Transition Period	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 10,201	$ 8,417
Short-term investments		16,915
Accounts receivable	373	602
Inventories, net — current	9,416	1,794
Prepaid expenses and other current assets	1,204	712
Total current assets	21,194	28,440
Restricted cash	2,001
Property and equipment, net	3,484	1,799
Right of use asset	6,013	1,963
Inventories, net — noncurrent	461	364
Goodwill	301
Intangible assets, net	400
Other noncurrent assets	23	8
Total assets	33,877	32,574
Current liabilities:
Accounts payable and accrued expenses	6,711	4,685
Amounts due to related parties	29	40
Debt — current	705	24
Unearned revenue — current		42
Operating lease liability — current	700	611
Other current liabilities	263	306
Total current liabilities	8,408	5,708
Debt — noncurrent	2,548	107
Operating lease liability — noncurrent	5,574	1,497
Common stock warrant liabilities	3,065	14,936
Other noncurrent liabilities	2,280	2,000
Total liabilities	21,875	24,248
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 10,832,203 and 8,646,149 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	51	49
Additional paid-in capital	231,954	214,826
Accumulated other comprehensive income		1
Accumulated deficit	(220,725)	(207,171)
Total Arcadia Biosciences stockholders’ equity	11,280	7,705
Non-controlling interest	722	621
Total stockholders' equity	12,002	8,326
Total liabilities and stockholders’ equity	$ 33,877	$ 32,574

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	10,832,203	8,646,149
Common stock, outstanding	10,832,203	8,646,149

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 314,000	$ 392,000	$ 904,000	$ 753,000
Operating expenses:
Research and development	1,762,000	1,931,000	5,999,000	5,387,000
Selling, general and administrative	4,292,000	4,477,000	11,689,000	10,434,000
Total operating expenses	7,895,000	6,585,000	21,151,000	16,145,000
Loss from operations	(7,581,000)	(6,193,000)	(20,247,000)	(15,392,000)
Interest expense	(23,000)	(3,000)	(32,000)	(3,000)
Other income, net		119,000	83,000	339,000
Change in fair value of common stock warrant liabilities	1,130,000	(7,777,000)	6,212,000	(6,790,000)
Loss on extinguishment of warrant liability	(682,000)		(635,000)
Offering costs		(336,000)		(702,000)
Net loss before income taxes	(7,156,000)	(14,190,000)	(14,619,000)	(22,548,000)
Income tax benefit (provision)	(9,000)	3,000	(15,000)	(14,000)
Net loss	(7,165,000)	(14,187,000)	(14,634,000)	(22,562,000)
Net loss attributable to non-controlling interest	(774,000)		(1,081,000)
Net loss attributable to common stockholders	$ (6,391,000)	$ (14,187,000)	$ (13,553,000)	$ (22,562,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)
Weighted-average number of shares used in per share calculations:
Basic and Diluted	10,719,618	6,942,612	9,570,259	5,596,545
Other comprehensive loss, net of tax
Unrealized losses on available-for-sale securities		$ (1,000)	$ (1,000)
Other comprehensive loss		(1,000)	(1,000)
Comprehensive loss attributable to common stockholders	$ (6,391,000)	(14,188,000)	(13,554,000)	$ (22,562,000)
Product
Revenues:
Total revenues	245,000	216,000	630,000	485,000
Operating expenses:
Cost of product revenues	1,841,000	177,000	3,463,000	324,000
License
Revenues:
Total revenues	10,000	17,000	110,000	17,000
Royalty
Revenues:
Total revenues	16,000		58,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 43,000	$ 159,000	$ 106,000	$ 251,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	June 2019 Offering [Member]	September 2019 Offering [Member]	June 2018 Warrants [Member]	May 2020 Warrant Transaction [Member]	May 2020 Warrants [Member]	June 2019 Purchase Agreement [Member]	March 2018 PIPE [Member]	July 2020 Warrants [Member]	Common Stock [Member]	Common Stock [Member]June 2019 Offering [Member]	Common Stock [Member]September 2019 Offering [Member]	Common Stock [Member]June 2018 Warrants [Member]	Common Stock [Member]June 2019 Purchase Agreement [Member]	Common Stock [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]June 2019 Offering [Member]	Additional Paid-In Capital [Member]September 2019 Offering [Member]	Additional Paid-In Capital [Member]June 2018 Warrants [Member]	Additional Paid-In Capital [Member]May 2020 Warrant Transaction [Member]	Additional Paid-In Capital [Member]May 2020 Warrants [Member]	Additional Paid-In Capital [Member]June 2019 Purchase Agreement [Member]	Additional Paid-In Capital [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]July 2020 Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2018	$ 12,815									$ 45						$ 191,136									$ (178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Issuance of shares related to employee stock purchase plan	8															8
Issuance of shares related to employee stock purchase plan, Shares										2,500
Stock-based compensation	422															422
Net (loss) income	(12,612)																								(12,612)
Stockholders Equity, Ending Balance at Mar. 31, 2019	633									$ 45						191,566									(190,978)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2019										4,777,419
Stockholders Equity, Beginning Balance at Dec. 31, 2018	12,815									$ 45						191,136									(178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Net (loss) income	(22,562)
Stockholders Equity, Ending Balance at Sep. 30, 2019	14,233									$ 49						214,423									(200,928)		$ 689
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2019										8,646,149
Stockholders Equity, Beginning Balance at Dec. 31, 2018	12,815									$ 45						191,136									(178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018										4,774,919
Net (loss) income	(28,900)
Stockholders Equity, Ending Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	$ 1	621
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2019										8,646,149
Stockholders Equity, Beginning Balance at Mar. 31, 2019	633									$ 45						191,566									(190,978)
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2019										4,777,419
Issuance of shares							$ 3,303							$ 2								$ 3,301
Issuance of shares, Shares														1,489,575
Issuance of placement agent warrants		$ 198															$ 198
Issuance of shares related to the exercise of warrants		$ 5,269									$ 1						$ 5,268
Issuance of shares related to the exercise of warrants, Shares											1,053,745
Offering costs							$ (487)															$ (487)
Stock-based compensation	389															389
Net (loss) income	4,237																								4,237
Stockholders Equity, Ending Balance at Jun. 30, 2019	13,542									$ 48						200,235									(186,741)
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2019										7,320,739
Issuance of shares related to employee stock purchase plan	10															10
Issuance of shares related to employee stock purchase plan, Shares										6,036
Issuance of shares related to employee stock option exercises	3															3
Issuance of shares related to employee stock option exercises, Shares										546
Reclassification of common stock warrant liability balance with exercise	7,016															7,016
Issuance of shares			$ 6,571									$ 1						$ 6,570
Issuance of shares, Shares												1,318,828
Issuance of placement agent warrants			326															326
Offering costs			$ (796)															$ (796)
Stock-based compensation	1,059															1,059
Unrealized losses on available-for-sale securities	(1)
Non-controlling interest contributions	689																										689
Net (loss) income	(14,187)																								(14,187)
Stockholders Equity, Ending Balance at Sep. 30, 2019	14,233									$ 49						214,423									(200,928)		689
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2019										8,646,149
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019										8,646,149
Issuance of shares related to employee stock purchase plan	14															14
Issuance of shares related to employee stock purchase plan, Shares										7,946
Stock-based compensation	772															772
Unrealized losses on available-for-sale securities	(1)																									(1)
Non-controlling interest contributions	689																										689
Net (loss) income	2,423																								2,525		(102)
Stockholders Equity, Ending Balance at Mar. 31, 2020	12,223									$ 49						215,612									(204,646)		1,208
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2020										8,654,095
Stockholders Equity, Beginning Balance at Dec. 31, 2019	8,326									$ 49						214,826									(207,171)	$ 1	621
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2019										8,646,149
Unrealized losses on available-for-sale securities	(1)
Net (loss) income	(14,634)
Stockholders Equity, Ending Balance at Sep. 30, 2020	12,002									$ 51						231,954									(220,725)		722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020										10,832,203
Stockholders Equity, Beginning Balance at Mar. 31, 2020	12,223									$ 49						215,612									(204,646)		1,208
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2020										8,654,095
Issuance of shares				$ 5,569									$ 1						$ 5,568
Issuance of shares, Shares													1,392,345
Issuance of investor warrants					$ 4,415															$ 4,415
Issuance of placement agent warrants						$ 215															$ 215
Stock-based compensation	595															595
Non-controlling interest contributions	493																										493
Net (loss) income	(9,893)																								(9,688)		(205)
Stockholders Equity, Ending Balance at Jun. 30, 2020	13,617									$ 50						226,405									(214,334)		1,496
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2020										10,046,440
Issuance of shares related to employee stock purchase plan	37															37
Issuance of shares related to employee stock purchase plan, Shares										11,721
Issuance of shares								$ 2,444							$ 1								$ 2,443
Issuance of shares, Shares															641,416
Issuance of investor warrants									$ 2,059															$ 2,059
Issuance of placement agent warrants									$ 101															$ 101
Stock-based compensation	477															477
Shares of common stock issued at closing of ISI transaction	432															432
Shares of common stock issued at closing of ISI transaction, Shares										132,626
Net (loss) income	(7,165)																								(6,391)		(774)
Stockholders Equity, Ending Balance at Sep. 30, 2020	$ 12,002									$ 51						$ 231,954									$ (220,725)		$ 722
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2020										10,832,203

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,165,000)	$ 2,423,000	$ (14,187,000)	$ (12,612,000)	$ (14,634,000)	$ (22,562,000)	$ (28,900,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	(1,130,000)		7,777,000		(6,212,000)	6,790,000
Loss on extinguishment of warrant liability					635,000
Offering costs			336,000			702,000
Depreciation					395,000	133,000
Lease amortization					745,000	530,000
(Gain) Loss on disposal of equipment					(8,000)	1,000
Net amortization of investment premium					(44,000)	(121,000)
Stock-based compensation					1,844,000	1,870,000
Write-down of inventory and prepaid production costs	1,500,000		0		3,063,000	0
Changes in operating assets and liabilities:
Accounts receivable					229,000	38,000
Unbilled revenue						3,000
Inventories					(9,609,000)	(1,411,000)
Prepaid expenses and other current assets					(1,157,000)	(36,000)
Other noncurrent assets					(15,000)
Accounts payable and accrued expenses					2,026,000	2,425,000
Amounts due to related parties					(11,000)	(1,000)
Other current liabilities					(43,000)	3,000
Unearned revenue					(42,000)	(16,000)
Operating lease payments					(629,000)	(534,000)
Net cash used in operating activities					(23,467,000)	(12,186,000)	(17,200,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment					8,000	1,000
Purchases of property and equipment					(2,038,000)	(878,000)
Acquisitions, net of cash acquired					(500,000)
Purchases of investments					(1,292,000)	(18,458,000)
Proceeds from sales and maturities of investments					18,250,000	18,050,000
Net cash provided by (used in) investing activities					14,428,000	(1,285,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings					3,108,000
Payments of transaction costs relating to extinguishment of warrant liability					(863,000)
Principal payments on notes payable					(26,000)	(2,000)
Proceeds from the exercise of warrants					9,372,000	5,269,000
Proceeds from ESPP purchases					51,000	21,000
Capital contributions received from non-controlling interest					1,182,000	689,000
Net cash provided by financing activities					12,824,000	22,014,000
Net increase in cash, cash equivalents and restricted cash					3,785,000	8,543,000
Cash, cash equivalents and restricted cash — beginning of period		$ 8,417,000		$ 11,998,000	8,417,000	11,998,000	11,998,000
Cash, cash equivalents and restricted cash — end of period	$ 12,202,000		$ 20,541,000		12,202,000	20,541,000	$ 8,417,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes					1,000	2,000
Cash paid for interest					7,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Fixed assets acquired with notes payable					37,000	139,000
Offering costs in accounts payable and accrued expenses at end of period						21,000
Reclassification of common stock warrant liability balance with warrant exercises						7,016,000
Right of use assets obtained in exchange for new operating lease liabilities					4,157,000	2,328,000
Purchases of fixed assets included in accounts payable and accrued expenses						6,000
March 2018 Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Purchase Agreement						10,000,000
June 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from warrant exercises, issuance of common stock and warrants from June 2019 Offering						7,500,000
Payments of offering costs						(663,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						86,000
September 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs						(776,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs						95,000
June 2018 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs						$ (24,000)
May 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					215,000
July 2020 Warrant Transaction [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock warrants issued to placement agent and included in offering costs					$ 101,000

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015. The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 7) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. The Company is closely monitoring how the spread of the novel coronavirus is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Verdeca and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC had no operations for the three and nine months ended September 30, 2020 and 2019, respectively, and had no assets or liabilities as of September 30, 2020 and December 31, 2019, respectively. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2020, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2020. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020. Restricted Cash Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the condensed consolidated balance sheets Liquidity, Capital Resources, and Going Concern As of September 30, 2020, the Company had an accumulated deficit of $220.7 million, and cash and cash equivalents of $10.2 million. For the nine months ended September 30, 2020, the Company had net losses of $14.6 million and net cash used in operations of $23.5 million. For the twelve months ended December 31, 2019, the Company had net losses of $28.9 million and net cash used in operations of $17.2 million. With cash and cash equivalents of $10.2 million as of September 30, 2020, the Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through November 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings, if necessary and available. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders and could have unfavorable terms. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that could restrict operations. If the Company is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs or operations. Any of these actions could materially harm the business, results of operations and financial condition. As previously disclosed, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak (“COVID-19”) and impact of related responses. The continued spread of the outbreak could materially harm the Company’s business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, the Company may not be able to achieve and implement such plans within one year after the date that the condensed consolidated

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326 Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement The Company adopted ASU No. 2018-13 on January 1, 2020 and expanded its disclosures for significant unobservable inputs used to develop Level 3 fair value measurements. There was no impact on the condensed consolidated financial statements. See Note 4. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments are effective for all entities for fiscal years beginning after December 15, 2020. of operations and comprehensive loss In April 2020, the FASB issued a staff question-and-answer (“Q&A”) document to respond to frequently asked questions about the accounting for lease concessions related to the effects of the COVID-19 pandemic. Under current GAAP, subsequent changes to lease payments that are not stipulated in the original lease contract are generally accounted for as lease modifications under Topic 842. The Q&A allows companies to make an accounting policy election to not evaluate lease concessions related to the effects of the COVID-19 pandemic as lease modifications. Entities that make this election then need to decide whether to apply the lease modification guidance in ASC 842 to the concession or account for the concession as if it were contemplated as part of the existing contract. The Company has not entered into any lease modifications that provide concessions related to the effects of the COVID-19 pandemic, and therefore has not evaluated its option to make this accounting policy election.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory	3. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded write-downs of wheat inventories, hemp seed inventories, and prepaid production costs of $1.5 million and $3.1 million for the three and nine months ended September 30, 2020, respectively. The $1.3 million write-down of hemp seed inventories related to Archipelago was due to regulatory changes. See Note 7. The developmental hemp seed varieties which did not meet regulatory and quality specifications are the cause for the additional $176,000 write-down. There were no such write-downs for the three and nine months ended September 30, 2019. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain, and GLA oil and seed. Raw materials inventories consist primarily of the cost to purchase hemp seeds and GLA seed production costs incurred by contracted cooperators. Goods in process inventories consist of costs to process hemp seed, hemp seed production costs incurred by Archipelago, grower fees and related costs for soybeans to be transferred to Verdeca, and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products, GoodHemp seed and GLA oil that are available for sale. Inventories, net consist of the following (in thousands): September 30, 2020 December 31, 2019 Raw materials $ 36 $ 67 Goods in process 4,079 188 Finished goods 5,762 1,903 Inventories $ 9,877 $ 2,158

Investments and Fair Value of F

Investments and Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2020
Investments And Fair Value Of Financial Instruments [Abstract]
Investments and Fair Value of Financial Instruments	4. Investments and Fair Value of Financial Instruments Investments The Company’s investments are “available-for-sale” investments and are free of trading restrictions. These investments are classified as short-term due to the maturity dates of the investments. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the cash equivalents and investment securities portfolio at September 30, 2020 and December 31, 2019, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value September 30, 2020 Cash equivalents: Money market funds $ 8,064 $ — $ — $ 8,064 Total investments $ 8,064 $ — $ — $ 8,064 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total investments $ 24,678 $ 1 $ — $ 24,679 The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2020. As of September 30, 2020, the Company did not have any fixed income securities that were in unrealized loss positions, and therefore has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the three and nine months ended September 30, 2020. Fair Value Measurement Fair value accounting is applied for all assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The fair value of the Company’s financial assets as of September 30, 2020 and December 31, 2019 were as follows: Fair Value Measurements at September 30, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 8,064 $ — $ — $ 8,064 Total Assets at Fair Value $ 8,064 $ — $ — $ 8,064 Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679 The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, accounts receivable, short-term investments, accounts payable, accrued liabilities and debt. For accounts receivable, accounts payable, accrued liabilities, and the current portion of debt the carrying amounts of these financial instruments as of September 30, 2020 and December 31, 2019 were considered representative of their fair values due to their short term to maturity or repayment. The carrying value of the noncurrent portion of debt is considered representative of their fair values due to the recency of their issuance related to the quarter ended September 30, 2020. Cash equivalents are carried at cost, which approximates their fair value. There were no changes in valuation techniques during 2020 or 2019. The valuation methodologies used for the Company’s instruments measured at fair value and their classification in the valuation hierarchy are summarized below: • Money market funds and treasury bills – Investments in money market funds and treasury bills are valued using the market approach and are classified within Level 1. • Commercial paper and corporate securities – Investments in commercial paper and corporate securities are valued using the market approach and are classified within Level 2. • Contingent liability – A contingent liability resulting from the Anawah acquisition, as described in Note 14, is classified within Level 3. The contingent liability was measured and recorded on a recurring basis as of September 30, 2020 and December 31, 2019 using unobservable quantitative inputs that would impact the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase . At September 30, 2020 and December 31, 2019, this liability was included on the condensed consolidated balance sheets as a noncurrent liability. • Purchase Agreement common stock warrant liability – The Company has outstanding warrants to purchase common stock that it issued to certain accredited investors and its placement agent on March 22, 2018 (as described in Note 10). The common stock warrants were classified as a liability within Level 3 based on the instrument’s adjustment features and a contingent cash payment feature . At September 30, 2020 and December 31, 2019, this liability was included on the condensed consolidated balance sheets as a noncurrent liability. • June 2018, June 2019 and September 2019 Offering common stock warrant liabilities – The Company has outstanding warrants to purchase common stock that it issued to certain accredited investors (as described in Note 10). The common stock warrants are classified as a liability within Level 3 due to a contingent cash payment feature . At September 30, 2020, the June 2019 and September 2019 warrant liabilities were included on the condensed consolidated balance sheets as noncurrent liabilities. At December 31, 2019, the June 2018, June 2019 and September 2019 warrant liabilities were included on the condensed consolidated balance sheets as noncurrent liabilities. The estimated fair value of the common stock warrant liabilities related to the March 2018 Purchase Agreement, the June 2018 Offering, the June 2019 Offering and the September 2019 Offering (the “warrant liabilities”) Volatility is considered by the Company to be a significant unobservable input and is calculated using a weighted average of historical stock prices of a combination of the Company and peer companies, due to the lack of sufficient historical data of the Company’s own stock price. A change in the mix or weighting of the peer companies could have resulted in a significantly lower (higher) fair value measurement as of . Volatility rates used in the measurement of the warrant liabilities ranged from 125.0% to 130.0%, and the weighted average was 127.2% The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liability Total Balance as of December 31, 2019 $ 4,579 $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936 Change in fair value (2,155 ) (1,426 ) (1,064 ) (1,567 ) — (6,212 ) Exercise of warrants (Note 10) (1,641 ) (4,018 ) — — — (5,659 ) ISI acquisition contingent consideration — — — — 280 280 Balance as of September 30, 2020 $ 783 $ — $ 929 $ 1,353 $ 2,280 $ 5,345

Industrial Seed Innovations Acq

Industrial Seed Innovations Acquisition	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Industrial Seed Innovations Acquisition	5. Industrial Seed Innovations Acquisition On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company. As a result of the acquisition, the Company acquired ISI’s commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI’s Rogue and Umpqua seed varieties are now part of Arcadia’s portfolio, alongside the Company’s GoodHemp line of genetically superior hemp seeds, transplants, and extracts. The acquisition has significantly broadened and accelerated commercialization of Arcadia’s hemp-related breeding platform, as well as established a breeding research and development facility in the Pacific Northwest, a key production area in the hemp industry. The purchase price consideration for the acquisition totaled an estimated $1,212,000, of which $500,000 in cash and $432,000, in the form of 132,626 shares of the Company’s common stock, was paid during the third quarter ended September 30, 2020. The remaining amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The cash consideration paid for the acquisition was funded by cash on hand. For the three months period ended September 30, 2020 no revenues from ISI were recorded, and expenses were immaterial. The pro forma impact of the acquisition to the historical financial results was determined to not be significant. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the ISI acquisition of approximately $67,000 included in selling, general and administrative expenses in the Company's Consolidated Statements of Operations and Comprehensive Loss. The following table presents the preliminary allocation of the purchase price of ISI assets acquired, based on their relative fair values, which have been assessed during the quarter ended September 30, 2020: Purchase Price Allocation Inventory $ 511 Intangible assets 400 Goodwill 301 Total consideration allocated $ 1,212 The former shareholders of ISI remain responsible for ISI’s pre-acquisition liabilities. Pursuant to the definitive acquisition agreement, the Company entered into a lease agreement with ISI for the use of land, equipment, greenhouses and buildings. The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.

Variable Interest Entity

Variable Interest Entity	9 Months Ended
	Sep. 30, 2020
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	6. Variable Interest Entity In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. The Company determined that a de facto agency relationship between the Company and Bioceres exists. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. Both the Company and Bioceres incur expenses in support of specific activities, as agreed upon by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amounts of $240,000 and $ 340,000

Consolidated Joint Venture

Consolidated Joint Venture	9 Months Ended
	Sep. 30, 2020
Equity Method Investments And Joint Ventures [Abstract]
Consolidated Joint Venture	7. Consolidated Joint Venture On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company (“Archipelago”) and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. The Company continued to cultivate hemp through third quarter of 2020 with the intention of producing CBD oil for sale. However, with the recently issued Drug Enforcement Agency (“DEA”) interim final ruling (“IFR”) and the expiration of the Hawaiian Industrial Pilot Program on October 31, 2020, Archipelago’s joint operating committee made the decision to temporarily cease operations in the manner in which it is currently configured. The DEA IFR specifies that should the THC content exceed 0.3% at any point during the extraction process, processers will be considered to be in possession of a Schedule I controlled substance. The Company will continue to monitor the regulatory environment and determine when and in what manner it is feasible and beneficial to re-enter the market. As a result, the Company destroyed the hemp plants that were currently in the ground and disposed of the biomass that had already been harvested, prior to October 31, 2020 as neither would have been able to be processed into CBD oil and remain in compliance with the regulatory framework effective November 1, 2020. The value of the plants and biomass totaled $1.3 million and was written off from inventory to cost of product revenues in the three months ended September 30, 2020. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2020, the Company and Legacy hold 50.75% and 49.25% percentage interests in Archipelago, respectively, and have made capital contributions to Archipelago of $1,927,000 and $1,871,000, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded loss to arrive at net loss attributable to common stockholders on the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2020, respectively. Legacy’s equity interests are presented as noncontrolling interests on the condensed c onsolidated balance sheets. Refer to Note 1 for basis of presentation.

Collaborative Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	8. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva AgriScience (“Corteva”) and involves a joint operating activity where both the Company and Corteva are active participants in the activities of the collaboration. The Company and Corteva participate in the research and development, and the Company has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Lessee Disclosure [Abstract]
Leases	9. Leases Operating Leases As of September 30, 2020, the Company leases office space in Davis, CA, Phoenix, AZ, and Molokai, HI, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to third parties. During the nine months ended September 30, 2020, the Company entered into three lease amendments that provide for additional office space in Davis, CA, and extend the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability, resulting in an additional $3.8 million operating lease liability and right of use asset. finance leases or material leases that have not yet commenced as of September 30, 2020. Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Balance Sheet Line Item September 30, 2020 December 31, 2019 Assets Operating lease assets Right of use asset $ 6,013 $ 1,963 Total leased assets $ 6,013 $ 1,963 Liabilities Current - Operating Operating lease liability- current $ 700 $ 611 Noncurrent - Operating Operating lease liability- noncurrent 5,574 1,497 Total leased liabilities $ 6,274 $ 2,108 Lease Cost Classification For the Three Months Ended September 30, 2020 For the Three Months Ended September 30, 2019 For the Nine Months Ended September 30, 2020 For the Nine Months Ended September 30, 2019 Operating lease cost SG&A and R&D Expenses $ 261 $ 177 $ 745 $ 529 Short term lease cost (1) R&D Expenses 109 45 303 138 Short term lease cost SG&A Expenses — — 3 — Sublease income (2) SG&A and R&D Expenses (12 ) (13 ) (34 ) (40 ) Net lease cost $ 358 $ 209 $ 1,017 $ 627 (1) Short term lease cost included in R&D expenses consists primarily of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate September 30, 2020 December 31, 2019 Weighted-average remaining lease term (years) 5.8 2.6 Weighted-average discount rate 6.6 % 7.0 %

Private Placement and Register

Private Placement and Registered Direct Offering	9 Months Ended
	Sep. 30, 2020
Warrants And Rights Note Disclosure [Abstract]
Private Placement and Registered Direct Offering	10. Private Placement and Registered Direct Offering Private Placement (2018) and July Warrant Exercise Transaction (2020) On March 22, 2018, the Company issued 300,752 shares of its common stock (“common stock”) and warrants to purchase up to 300,752 shares of common stock with an initial exercise price equal to $45.75 (the “March 2018 Warrants”), in a private placement (the “March 2018 Private Placement”) in accordance with a securities purchase agreement (the “March 2018 Purchase Agreement”) entered into with certain institutional and accredited investors (collectively, the “Purchasers”) on March 19, 2018. The number of shares of common stock, the number and exercise price of the March 2018 Warrants issued to the Purchasers were subject to adjustments as provided in the March 2018 Purchase Agreement. The March 2018 Warrants are immediately exercisable, subject to certain ownership limitations, and expire five years after the date of issuance. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the Purchasers was 1,201,634, the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $10.7258. These condensed consolidated financial statements reflect these additional issuances. The adjustment feature for the common stock and the March 2018 Warrants were determined to be liabilities based on each instrument’s adjustment features and the contingent cash payment feature of the common stock warrants. The March 2018 Warrant liability was marked-to-market and valued at $0.8 million at September 30, 2020, resulting in income of $0.2 million and income of $2.2 recognized during the three and nine months ended September 30, 2020, respectively. The March 2018 Warrant liability was marked-to-market and valued at $3.8 million at September 30, 2019, resulting in expense of $1.6 million and $1.6 million recognized during the three and nine months ended September 30, 2019, respectively. On July 8, 2020, pursuant to the terms of a letter agreement entered into on July 6, 2020 (the “transaction date”), an existing accredited investor exercised its March 2018 Warrants (the “July 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 641,416 shares of the Company’s common stock at a reduced exercise price of $3.975 per share for gross proceeds of $2.6 million. The 641,416 shares of common stock sold in the July 2020 Warrant Exercise Transaction are registered for resale pursuant to a Registration Statement on Form S-3 (File No. 333-224061 ) . The July 2020 Warrant Exercise Transaction closed on July 8, 2020. As consideration for the exercise of the March 2018 Warrants, the Company issued new unregistered warrants to purchase up to 641,416 shares of common stock (the “July 2020 Warrants”) at an exercise price of $3.85 per share with an exercise period of five and one-half years from the date of issuance. The aggregate net proceeds received by the Company for the July 2020 Warrant Exercise Transaction were $2.3 million, consisting of gross proceeds of $2.6 million less offering costs of $269,000. The Company currently intends to use the net proceeds from the offering to pay for general corporate expenses. The March 2018 Warrants Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Equity The July 2020 Warrants do not include the same cash penalty provisions for untimely SEC filings, and therefore were determined to be an equity instrument. recognized a loss on extinguishment of warrant liability of approximately $682,000 in the nine months ended September 30, 2020. The loss on extinguishment of warrant liability is comprised of the difference between the reacquisition price and the carrying amount of the March 2018 Warrants. The shares of common stock issued were valued at $2.4 million as of the transaction date. The July 2020 Warrants were valued at $2.1 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 126 percent, stock price of $3.73 and risk-free rate of 0.30%. The carrying value of the March 2018 Warrants was valued at $1.6 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 151 percent, stock price of $3.81 and risk-free rate of 0.19%. The March 2018 Warrants were marked-to-market and valued at $3.8 million at September 30, 2019, resulting in expense of $1.6 million for the nine months ended September 30, 2019. Offering Costs (July 2020 Warrants) In connection with the July 2020 Warrant Exercise Transaction, Registration of July Warrant Shares (2020) On August 13, 2020, the Company filed a registration statement on Form S-3/A (File No. 333-239641 ) Registered Direct Offering (2018) and May Warrant Exercise Transaction (2020) On June 11, 2018, the Company entered into agreements with several institutional and accredited investors (the “June 2018 Purchase Agreement”) for the purchase of 1,392,345 shares of its common stock at a purchase price of $9.93 per share. Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 1,392,345 shares of common stock at a purchase price per warrant of $0.125 (the “June 2018 Warrants”). The June 2018 Warrants have an exercise price of $9.94 per share. Subject to certain ownership limitations, the June 2018 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. On May 18, 2020, pursuant to the terms of letter agreements entered into on May 14, 2020 (the “transaction date”), several existing accredited investors exercised the June 2018 Warrants (the “May 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 1,392,345 shares of the Company’s common stock at a reduced exercise price of $4.90 per share for gross proceeds of $6.8 million. The 1,392,345 shares of common stock sold in the May 2020 Warrant Exercise Transaction are registered for resale pursuant to a Registration Statement on Form S-1 (File No. 333-229047 ) . The May 2020 Warrant Exercise Transaction closed on May 18, 2020. As consideration for the exercise of the June 2018 Warrants, the Company issued new unregistered warrants to purchase up to 1,392,345 shares of common stock (the “May 2020 Warrants”) at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance. The aggregate net proceeds received by the Company for the May 2020 Warrant Exercise Transaction were $6.2 million, consisting of gross proceeds of $6.8 million less offering costs of $594,000. The Company intends to use the net proceeds from this offering to pursue a range of near-term inorganic growth opportunities within the Company’s hemp business unit. The June 2018 Warrants Distinguishing Liabilities from Equity Derivatives and Hedging – Contracts in Entity’s Own Equity The May 2020 Warrants do not include the same cash penalty provisions for untimely SEC filings, and therefore were determined to be an equity instrument. recognized a gain on extinguishment of warrant liability of approximately $47,000 in the nine months ended September 30, 2020. The gain on extinguishment of warrant liability is comprised of the difference between the reacquisition price and the carrying amount of the June 2018 Warrants. The shares of common stock issued were valued at $5.6 million as of the transaction date. The May 2020 Warrants were valued at $4.4 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 128 percent, stock price of $3.81 and risk-free rate of 0.38%. The carrying value of the June 2018 Warrants was valued at $4.0 million which was calculated using the Black-Scholes Model with the following assumptions: volatility of 140 percent, stock price of $4.00 and risk-free rate of 0.28%. The June 2018 Warrants were marked-to-market and valued at $4.5 million at September 30, 2019, resulting in expense of $1.9 million and $1.8 million recognized during the three and nine months ended September 30, 2019, respectively. Offering Costs (May 2020 Warrants) In connection with the May 2020 Warrant Exercise Transaction, Registration of May Warrant Shares (2020) On July 2, 2020, the Company filed a registration statement on Form S-3 (File No. 333-239641 ) Registered Direct Offering (June 2019) On June 12, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “June 2019 Purchase Agreement”) relating to the offering and sale of . Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 1,489,575 shares of common stock at a purchase price per warrant of $0.125 (the “June 2019 Warrants”). The June 2019 Warrants have an exercise price of $5.00 per share. Subject to certain ownership limitations, the June 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The June 2019 Warrants The June 2019 Warrant liability was marked-to-market and valued at $1.6 million at September 30, 2019, resulting in expense of $5.3 million and $4.5 million recognized during the three and nine months ended September 30, 2019, respectively. Registered Direct Offering (September 2019) On September 5, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “September 2019 Purchase Agreement”) relating to the offering and sale of . Additionally, in a concurrent private placement, the Company issued to the investors unregistered warrants to purchase up to 659,414 shares of common stock at a purchase price per warrant of $0.125 (the “ 2019 Warrants”). The 2019 Warrants have an exercise price of $7.52 per share. Subject to certain ownership limitations, the September 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The September 2019 Warrants September 2019 Warrants

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	11. Debt Vehicle Loans The Company has various vehicle loans that mature in 2024 and have interest rates that range from 7.64% to 8.00%. As of September 30, 2020, the outstanding balance of vehicle loans was $145,000. Paycheck Protection Program Note On April 16, 2020, the Company borrowed $1.1 million and entered into a promissory note for the same amount (the “PPP Note”) under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. The PPP Note matures on April 16, 2022, bears an interest rate of 1.00% per year, and is payable monthly beginning on November 2, 2020. The Company may prepay the PPP Note at any time prior to maturity with no prepayment penalties. The principal amount of the PPP Note and accrued interest are eligible for forgiveness if the proceeds are used for qualifying expenses, including payroll, rent, and utilities during the eight week period commencing on April 16, 2020. The Company will be obligated to repay any portion of the principal amount of the PPP Note that is not forgiven, together with accrued interest thereon, until such unforgiven portion is paid in full. The Company intends to apply for loan forgiveness within the required timeframe. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part. As of September 30, 2020, the outstanding balance of the PPP Note was $1.1 million. Promissory Note On June 26, 2020, executed a promissory note (the “Note") in the amount of $2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $2.0 million. Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%. condensed consolidated balance sheets as of September 30, 2020 . As of September 30, 2020, the outstanding balance of the Note was $2.0 million. Maturities of current and noncurrent debt as of September 30, 2020 are as follows (in thousands): Years ending December 31, Amounts Remainder of 2020 $ 126 2021 774 2022 285 2023 2,039 2024 29 Thereafter — Total $ 3,253

Stock-Based Compensation and Wa

Stock-Based Compensation and Warrants	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]
Stock-Based Compensation and Warrants	12. Stock-Based Compensation and Warrants Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when the 2006 Plan was terminated for future awards. The 2006 Plan continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over a two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years after grant. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. As of September 30, 2020, a total of 1,047,188 shares of common stock were reserved for issuance under the 2015 Plan, of which 85,532 shares of common stock are available for future grant. As of September 30, 2020, a total of 19,227 and 961,656 options are outstanding under the 2006 and 2015 Plans, respectively. A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2019 661,701 $ 21.60 $ 305 Options granted 491,494 4.32 Options exercised — — Options forfeited (131,849 ) 6.39 Options expired (40,463 ) 48.57 Outstanding — Balance at September 30, 2020 980,883 $ 13.87 $ 1 Vested and expected to vest — September 30, 2020 965,445 $ 14.03 $ 1 Exercisable —September 30, 2020 540,267 $ 21.51 $ — As of September 30, 2020, there was $1.2 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.7 years. The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Model with the following weighted-average assumption. There were 491,494 and 186,571 options granted during the nine months ended September 30, 2020 and 2019, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Expected term (years) 6.01 6.24 6.50 7.13 Expected volatility 230% 99% 133% 99% Risk-free interest rate 0.38% 1.84% 1.03% 2.05% Dividend yield — — — — Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. The ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period. As of September 30, 2020, the number of shares of common stock reserved for future issuance under the ESPP is 105,036. The ESPP provides for automatic annual increases in the shares available for purchase on January 1 of each year. As of September 30, 2020, 35,056 shares had been issued under the ESPP. The Company recorded $12,200 and $4,300 of stock compensation expense for the three months ended September 30, 2020 and 2019, respectively, and $40,500 and $6,000 for the nine months ended September 30, 2020 and 2019, respectively. Warrants As of September 30, 2020, the Company has 4,450,689 common stock warrants outstanding with a weighted average exercise price of $6.31. The expiration of the warrants ranges from July 2021 to December 2025. In connection with the Series D preferred stock financing in the first half of 2014, the Company issued warrants, exercisable as of the issuance date, to the Series D preferred stock investors to purchase an aggregate of 61,397 shares of common stock at an exercise price of $363.20 per share and to the placement agents to purchase 1,674 shares of common stock at $268.80. Of the 63,071 warrants issued, 1,759 expired on March 28, 2019 and the remaining 61,312 expired in the second quarter of 2019, along with those issued to the placement agents. As of September 30, 2020, 656,454 common stock warrants are outstanding that were issued in the March 2018 Private Placement. Of the total, 641,416 shares have a purchase price of $10.7258 and the remaining 15,038 common stock warrants have an exercise price of $41.5625. See Note 10. As of September 30, 2020, 69,617 common stock warrants are outstanding in accordance with the June 2018 Offering, all of which have an exercise price of $12.568. See Note 10. In connection with a professional services agreement with a non-affiliated third party, executed in April 2019, the Company issued 45,154 warrants (“Service Warrants”) at an exercise price of $6.18. The Service Warrants vest ratably over 12 months and expire in five years from the date of issuance. The Service Warrants are cancelable immediately prior to a change of control subsequent to the termination/expiration of the advisory agreement. The Company also issued 100,000 performance-based warrants (“Performance Warrants”) at an exercise price of $6.18 and vest in 1/6 increments upon the achievement of a qualifying milestone as defined within the agreement. The Performance Warrants expire in five years from the date of issuance and are cancelable immediately prior to a change of control subsequent to the sixth month anniversary of the termination/expiration of the advisory agreement. The Service and Performance Warrants In June 2019, concurrent with the June 2019 Offering and pursuant to the June 2019 Purchase Agreement, the Company commenced a private placement whereby it issued and sold warrants exercisable for an aggregate of 1,489,575 shares of common stock, which equals 100% of the shares of common stock sold in the June 2019 Offering, with a purchase price of $0.125 per underlying warrant share and with an exercise price of $5.00 per share. The June 2019 Warrants are exercisable upon issuance and will expire five and a half years from the date of issuance. In August and September 2019, investors exercised a portion of the June 2019 Warrants and purchased 1,053,745 shares of common stock. The Company also issued warrants to the placement agents to purchase a total of 74,479 shares of common stock with an exercise price equal to $6.2938. The placement agent warrants are exercisable upon issuance and will expire five years from the date of issuance. As of September 30, 2020, the investors and placement agent hold outstanding warrants to purchase 510,309 shares of common stock warrants issued pursuant to the June 2019 Offering. See Note 10. In July 2019, the Company issued warrants to purchase 10,000 shares of common stock to an independent contractor at an exercise price of $2.19 and in August 2019, the Company issued warrants to purchase 20,000 shares of common stock to two affiliated third-parties at an exercise price of $1.92. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants issued in July vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. The August warrants vested on the issuance date of August 5, 2019 and expire two years from the date of issuance. As such, stock compensation expense associated with the August warrants was recognized as vested on the issuance date. For the warrants issued in July 2019, stock compensation expense of $2,000 and $10,000 was recognized during the three and nine months ended September 30, 2020. In September 2019, concurrent with the September 2019 Offering and pursuant to the September 2019 Purchase Agreement, the Company commenced a private placement whereby it issued and sold warrants exercisable for an aggregate of 659,414 shares of common stock, which equals 50% of the shares of common stock sold in the September 2019 Offering, with a purchase price of $0.125 per underlying warrant share and with an exercise price of $7.52 per share. The September 2019 Warrants are exercisable upon issuance and will expire five and a half years from the date of issuance. The Company also issued warrants to the placement agents to purchase a total of 65,942 shares of common stock with an exercise price equal to $9.4781. The placement agent warrants are exercisable upon issuance and will expire five years from the date of issuance. As of September 30, 2020, all 725,356 common stock warrants are outstanding that were issued with the September 2019 Offering. See Note 10. In February 2020, the Company issued warrants to purchase 10,000 shares of common stock to an independent contractor at an exercise price of $4.91. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. Stock compensation expense of $9,400 and $28,200 associated with these warrants was recognized during the three and nine months ended September 30, 2020, respectively. In connection with an extension of the professional services agreement with a non-affiliated third party, executed in April 2019, the Company issued an additional 150,000 warrants to purchase shares of common stock in February 2020 at an exercise price of $4.71. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. The warrants vest ratably over 12 months and expire two years from the date of issuance. As such, stock compensation expense associated with these warrants is recognized ratably over the 12-month service period. Stock compensation expense of $135,400 and $406,200 associated with these warrants was recognized during the three and nine months ended September 30, 2020, respectively. In connection with a professional services agreement with a non-affiliated third party, executed in March 2020, the Company issued warrants to purchase 18,350 shares of common stock at an exercise price of $2.50. The warrants vested on the issuance date and expire in three years from the date of issuance. The warrants are cancelable immediately prior to a change of control subsequent to the termination/expiration of the advisory agreement. These warrants were determined to be equity instruments and were measured on the grant date using the Black Scholes Model. As such, stock compensation expense associated with these warrants was recognized as vested on the issuance date. Stock compensation expense of $0 and $36,700 was recognized during the three and nine months ended September 30, 2020, respectively. In May 2020, in consideration for the exercise of the June 2018 Warrants in the May 2020 Warrant Exercise Transaction, the Company issued warrants to purchase 1,392,345 shares of common stock at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance. The Company also issued placement agent warrants to purchase a total of 69,617 shares of common stock See Note 10. In July 2020, in consideration for the exercise of the March 2018 Warrants in the July 2020 Warrant Exercise Transaction, the Company issued warrants to purchase 641,416 shares of common stock at an exercise price of $3.85 per share with an exercise period of five and one-half years from the date of issuance. The Company also issued placement agent warrants to purchase a total of 32,071 shares of common stock See Note 10.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company’s effective tax rate was -0.1% and -0.1% for the three and nine months ended September 30, 2020, and was 0.0% and -0.1% for the three and nine months ended September 30, 2019. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets and foreign withholding taxes. The Company experienced an ownership change under IRC Section 382 as a result of the common shares issued in connection with the June 2018 Offering. This ownership change limited the Company’s ability to utilize its net operating loss carryforwards prior to expiration and certain net operating loss carryforwards were written off as a result. The Company is currently conducting additional an alysis regarding the valuation of the Company at the time of the ownership change to assess what, if any, portion of the limitation may be reversed. A During the nine months ended September 30, 2020, there were no material changes to the Company’s uncertain tax positions.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Leases The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9. Contingent Liability Related to the Anawah Acquisition On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs, thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As a result, the Company recognized a gain of $1.0 million in the consolidated statements of operations and comprehensive loss. Contingent Liability Related to the ISI Acquisition On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company. A portion of the purchase price consideration for the acquisition in the amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. See Note 5. Contracts The Company has entered into a non-cancelable agreement with an unrelated party to provide research and development services. The agreement requires the Company to pay certain minimum funding commitments. The following table sets forth the minimum funding requirements under this agreement as of September 30, 2020 (in thousands): Years ending December 31, Amounts Remainder of 2020 $ 500 2021 750 2022 — 2023 — 2024 — Thereafter — Total $ 1,250

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Share	15. Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Securities that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Options to purchase common stock 980,883 691,001 980,883 691,001 Warrants to purchase common stock 4,450,689 4,170,651 4,450,689 4,170,651 Total 5,431,572 4,861,652 5,431,572 4,861,652 The following table sets forth the computation of basic and diluted net loss per common share (in thousands, except share and per share amounts): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Net loss per share - Basic Numerator: Net loss attributable to common stockholders $ (6,391 ) $ (14,187 ) $ (13,553 ) $ (22,562 ) Denominator: Weighted average number of common shares outstanding 10,719,618 6,942,612 9,570,259 5,596,545 Basic net loss per share attributable to common stockholders: $ (0.60 ) $ (2.04 ) $ (1.42 ) $ (4.03 ) Net loss per share - Diluted Numerator: Net loss attributable to common stockholders $ (6,391 ) $ (14,187 ) $ (13,553 ) $ (22,562 ) Denominator: Weighted average number of common shares outstanding 10,719,618 6,942,612 9,570,259 5,596,545 Effect of dilutive stock options — — — — Effect of dilutive warrants — — — — Weighted average number of common shares outstanding - diluted 10,719,618 6,942,612 9,570,259 5,596,545 Diluted net loss per share attributable to common stockholders: $ (0.60 ) $ (2.04 ) $ (1.42 ) $ (4.03 )

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	16. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to JSF. JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $29,000 and $40,000 as of September 30, 2020 and December 31, 2019, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. The Company currently leases land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company grows hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $1,200 per acre per year. The Company engaged a third-party contractor to construct a fence on the property to adhere to the rules of the hemp pilot program. Out of pocket costs to build this fence were approximately $126,400. Mr. Comcowich supplied materials to the contractor and received payments from the contractor totaling approximately $44,000. In March and April 2020, the Company entered into two lease amendments for two additional 10-acre parcels and two additional 15-acre parcels, at the same lease rate of $1,200 per acre per year, and with a term of two years. The Company made lease payments in the amount of $36,000 and $84,000 for the three and nine months ended September 30, 2020, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events Verdeca LLC Sale Transaction On November 12, 2020, Arcadia Biosciences, Inc. (the “Company”) entered into a Master Transaction Agreement (the “Agreement”) with Bioceres Crop Solutions Corp. (“BIOX”) pursuant to which (i) the Company sold all of its memberships interests it owned in Verdeca, LLC (“Verdeca”) to Bioceres, Inc., a wholly owned subsidiary of BIOX, and (ii) the Company and BIOX entered into a license agreement for certain intellectual property rights, including rights to the Company’s HB4 soybean trait and its GoodWheat portfolio of specialty wheat products in South and Central America. Prior to the transaction, Verdeca was equally owned by the Company and Bioceres, Inc. In consideration for the sale of the membership interests in Verdeca and entering into the license agreement, on November 12, 2020, BIOX paid the Company $5,000,000 in cash and issued the Company 1,875,000 shares of BIOX common stock. BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or if China approves the HB4 soybean trait for “food and feed”. In addition to the above payments, BIOX will also pay the Company quarterly royalty payments equal to six percent (6%) for the net revenues BIOX, or its affiliates, receive from HB4 soybean sales and twenty-five percent (25%) from wheat sales; provided that royalty payments for HB4 soybeans shall not exceed $10,000,000. The Company agreed not to sell or transfer any shares of BIOX common stock it received in this transaction for a period of 180 days without the prior written consent of BIOX, subject to certain exceptions allowing the Company to pledge shares to a lender as collateral. In addition, by December 12, 2020, the Company is required to seek consents from certain third parties who have right of first refusal or other similar rights to the traits being licensed by the Company to BIOX. If a third party exercises their rights of first refusal on the same terms and conditions as agreed upon by BIOX, then the Company has an option to pay BIOX $5,000,000 or 625,000 shares of BIOX common stock. Upon such payment, BIOX shall have no further rights to such trait which was subject to the right of first refusal. The Company entered into a pledge and security agreement with BIOX for the 625,000 shares of BIOX common stock that are subject to the potential clawback.

Description of Business and B_2

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Organization	Organization Arcadia Biosciences, Inc. (the “Company”) was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015. The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 6), which is jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 7) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. The Company is closely monitoring how the spread of the novel coronavirus is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Verdeca and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC had no operations for the three and nine months ended September 30, 2020 and 2019, respectively, and had no assets or liabilities as of September 30, 2020 and December 31, 2019, respectively. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $774,000 and $1,081,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the three and nine months ended September 30, 2020, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets as of September 30, 2020. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2020.
Restricted Cash	Restricted Cash Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the condensed consolidated balance sheets
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern As of September 30, 2020, the Company had an accumulated deficit of $220.7 million, and cash and cash equivalents of $10.2 million. For the nine months ended September 30, 2020, the Company had net losses of $14.6 million and net cash used in operations of $23.5 million. For the twelve months ended December 31, 2019, the Company had net losses of $28.9 million and net cash used in operations of $17.2 million. With cash and cash equivalents of $10.2 million as of September 30, 2020, the Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through November 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings, if necessary and available. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders and could have unfavorable terms. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that could restrict operations. If the Company is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned development programs or operations. Any of these actions could materially harm the business, results of operations and financial condition. As previously disclosed, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak (“COVID-19”) and impact of related responses. The continued spread of the outbreak could materially harm the Company’s business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, the Company may not be able to achieve and implement such plans within one year after the date that the condensed consolidated

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): September 30, 2020 December 31, 2019 Raw materials $ 36 $ 67 Goods in process 4,079 188 Finished goods 5,762 1,903 Inventories $ 9,877 $ 2,158

Investments and Fair Value of_2

Investments and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2020
Investments And Fair Value Of Financial Instruments [Abstract]
Summary of Amortized Cost and Fair Value of the Cash Equivalents and Available-For-Sale Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the cash equivalents and investment securities portfolio at September 30, 2020 and December 31, 2019, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value September 30, 2020 Cash equivalents: Money market funds $ 8,064 $ — $ — $ 8,064 Total investments $ 8,064 $ — $ — $ 8,064 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total investments $ 24,678 $ 1 $ — $ 24,679
Summary of Fair Value of Financial Assets	The fair value of the Company’s financial assets as of September 30, 2020 and December 31, 2019 were as follows: Fair Value Measurements at September 30, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 8,064 $ — $ — $ 8,064 Total Assets at Fair Value $ 8,064 $ — $ — $ 8,064 Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679
Summary of Changes in Fair Value of Liabilities	The following table summarizes the changes in the fair value of the Company’s Level 3 liabilities (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liability Total Balance as of December 31, 2019 $ 4,579 $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936 Change in fair value (2,155 ) (1,426 ) (1,064 ) (1,567 ) — (6,212 ) Exercise of warrants (Note 10) (1,641 ) (4,018 ) — — — (5,659 ) ISI acquisition contingent consideration — — — — 280 280 Balance as of September 30, 2020 $ 783 $ — $ 929 $ 1,353 $ 2,280 $ 5,345

Industrial Seed Innovations A_2

Industrial Seed Innovations Acquisition (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values	The following table presents the preliminary allocation of the purchase price of ISI assets acquired, based on their relative fair values, which have been assessed during the quarter ended September 30, 2020: Purchase Price Allocation Inventory $ 511 Intangible assets 400 Goodwill 301 Total consideration allocated $ 1,212

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Balance Sheet Line Item September 30, 2020 December 31, 2019 Assets Operating lease assets Right of use asset $ 6,013 $ 1,963 Total leased assets $ 6,013 $ 1,963 Liabilities Current - Operating Operating lease liability- current $ 700 $ 611 Noncurrent - Operating Operating lease liability- noncurrent 5,574 1,497 Total leased liabilities $ 6,274 $ 2,108 Lease Cost Classification For the Three Months Ended September 30, 2020 For the Three Months Ended September 30, 2019 For the Nine Months Ended September 30, 2020 For the Nine Months Ended September 30, 2019 Operating lease cost SG&A and R&D Expenses $ 261 $ 177 $ 745 $ 529 Short term lease cost (1) R&D Expenses 109 45 303 138 Short term lease cost SG&A Expenses — — 3 — Sublease income (2) SG&A and R&D Expenses (12 ) (13 ) (34 ) (40 ) Net lease cost $ 358 $ 209 $ 1,017 $ 627 (1) Short term lease cost included in R&D expenses consists primarily of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate September 30, 2020 December 31, 2019 Weighted-average remaining lease term (years) 5.8 2.6 Weighted-average discount rate 6.6 % 7.0 %

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Maturities of Current and Noncurrent Debt	Maturities of current and noncurrent debt as of September 30, 2020 are as follows (in thousands): Years ending December 31, Amounts Remainder of 2020 $ 126 2021 774 2022 285 2023 2,039 2024 29 Thereafter — Total $ 3,253

Stock-Based Compensation and _2

Stock-Based Compensation and Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2019 661,701 $ 21.60 $ 305 Options granted 491,494 4.32 Options exercised — — Options forfeited (131,849 ) 6.39 Options expired (40,463 ) 48.57 Outstanding — Balance at September 30, 2020 980,883 $ 13.87 $ 1 Vested and expected to vest — September 30, 2020 965,445 $ 14.03 $ 1 Exercisable —September 30, 2020 540,267 $ 21.51 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The fair value of stock option awards to employees, executives, directors, and other service providers was estimated at the date of grant using the Black-Scholes Model with the following weighted-average assumption. There were 491,494 and 186,571 options granted during the nine months ended September 30, 2020 and 2019, respectively. Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Expected term (years) 6.01 6.24 6.50 7.13 Expected volatility 230% 99% 133% 99% Risk-free interest rate 0.38% 1.84% 1.03% 2.05% Dividend yield — — — —

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement	The following table sets forth the minimum funding requirements under this agreement as of September 30, 2020 (in thousands): Years ending December 31, Amounts Remainder of 2020 $ 500 2021 750 2022 — 2023 — 2024 — Thereafter — Total $ 1,250

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would have been anti-dilutive were as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Options to purchase common stock 980,883 691,001 980,883 691,001 Warrants to purchase common stock 4,450,689 4,170,651 4,450,689 4,170,651 Total 5,431,572 4,861,652 5,431,572 4,861,652
Summary of Computation of Basic and Diluted Net Loss Per Common Share	The following table sets forth the computation of basic and diluted net loss per common share (in thousands, except share and per share amounts): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Net loss per share - Basic Numerator: Net loss attributable to common stockholders $ (6,391 ) $ (14,187 ) $ (13,553 ) $ (22,562 ) Denominator: Weighted average number of common shares outstanding 10,719,618 6,942,612 9,570,259 5,596,545 Basic net loss per share attributable to common stockholders: $ (0.60 ) $ (2.04 ) $ (1.42 ) $ (4.03 ) Net loss per share - Diluted Numerator: Net loss attributable to common stockholders $ (6,391 ) $ (14,187 ) $ (13,553 ) $ (22,562 ) Denominator: Weighted average number of common shares outstanding 10,719,618 6,942,612 9,570,259 5,596,545 Effect of dilutive stock options — — — — Effect of dilutive warrants — — — — Weighted average number of common shares outstanding - diluted 10,719,618 6,942,612 9,570,259 5,596,545 Diluted net loss per share attributable to common stockholders: $ (0.60 ) $ (2.04 ) $ (1.42 ) $ (4.03 )

Description of Business and B_3

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounting Policies [Line Items]
VIEs Operations	$ (7,581,000)			$ (6,193,000)			$ (20,247,000)	$ (15,392,000)
Net loss attributable to non-controlling interest	(774,000)						(1,081,000)
Accumulated deficit	(220,725,000)						(220,725,000)		$ (207,171,000)
Cash and cash equivalents	10,201,000						10,201,000		8,417,000
Net (loss) income	(7,165,000)	$ (9,893,000)	$ 2,423,000	(14,187,000)	$ 4,237,000	$ (12,612,000)	(14,634,000)	(22,562,000)	(28,900,000)
Net cash used in operations							(23,467,000)	(12,186,000)	(17,200,000)
Verdeca LLC [Member]
Accounting Policies [Line Items]
VIEs Operations	0			$ 0			0	$ 0
VIEs assets or liabilities	$ 0						$ 0		$ 0

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201813Member
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 1, 2020

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Inventory Current And Noncurrent [Line Items]
Write-downs of wheat inventories, hemp seed inventories, and prepaid production	$ 1,500,000	$ 0	$ 3,063,000	$ 0
Archipelago
Inventory Current And Noncurrent [Line Items]
Write-down of hemp seed inventories	1,300,000
Additional write-down of hemp seed inventories	$ 176,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 36	$ 67
Goods in process	4,079	188
Finished goods	5,762	1,903
Inventories	$ 9,877	$ 2,158

Investments and Fair Value of_3

Investments and Fair Value of Financial Instruments - Summary of Amortized Cost and Fair Value of the Cash Equivalents and Available-For-Sale Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 8,064	$ 24,678
Unrealized Gains	0	1
Unrealized Losses	0	0
Fair Value	8,064	24,679
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	8,064	6,864
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 8,064	6,864
Cash Equivalents [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		900
Unrealized Gains		0
Unrealized Losses		0
Fair Value		900
Short-term Investments [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		12,119
Unrealized Gains		0
Unrealized Losses		0
Fair Value		12,119
Short-term Investments [Member] | Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,495
Unrealized Gains		1
Unrealized Losses		0
Fair Value		1,496
Short-term Investments [Member] | Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,300
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 3,300

Investments and Fair Value of_4

Investments and Fair Value of Financial Instruments - Additional Information (Detail)	Sep. 30, 2020USD ($)Security
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Number of fixed income securities in unrealized loss position | Security	0
Other-than-temporary impairments associated with credit losses required to be recognized	$ 0
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	125
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	130
Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Warrants, measurement input	127.2

Investments and Fair Value of_5

Investments and Fair Value of Financial Instruments - Summary of Fair Value of Financial Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets at Fair Value
Total Assets at Fair Value	$ 8,064	$ 24,679
Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	8,064	8,360
Level 1 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	16,319
Level 2 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	8,064	6,864
Money Market Funds [Member] | Level 1 [Member]
Assets at Fair Value
Cash equivalents	8,064	6,864
Money Market Funds [Member] | Level 2 [Member]
Assets at Fair Value
Cash equivalents	0	0
Money Market Funds [Member] | Level 3 [Member]
Assets at Fair Value
Cash equivalents	$ 0	0
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Commercial Paper [Member] | Level 1 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		0
Commercial Paper [Member] | Level 2 [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Commercial Paper [Member] | Level 3 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		0
Corporate Securities [Member]
Assets at Fair Value
Short-term investments		3,300
Corporate Securities [Member] | Level 1 [Member]
Assets at Fair Value
Short-term investments		0
Corporate Securities [Member] | Level 2 [Member]
Assets at Fair Value
Short-term investments		3,300
Corporate Securities [Member] | Level 3 [Member]
Assets at Fair Value
Short-term investments		$ 0

Investments and Fair Value of_6

Investments and Fair Value of Financial Instruments - Summary of Changes in Fair Value of Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	$ 16,936
Change in fair value	(6,212)
Exercise of warrants (Note 10)	(5,659)
ISI acquisition contingent consideration	280
Balance as of September 30, 2020	5,345
Common Stock Warrant Liability [Member] | Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	4,579
Change in fair value	(2,155)
Exercise of warrants (Note 10)	(1,641)
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	783
Common Stock Warrant Liability [Member] | June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	5,444
Change in fair value	(1,426)
Exercise of warrants (Note 10)	(4,018)
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	0
Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	1,993
Change in fair value	(1,064)
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	929
Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	2,920
Change in fair value	(1,567)
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	0
Balance as of September 30, 2020	1,353
Contingent Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2019	2,000
Change in fair value	0
Exercise of warrants (Note 10)	0
ISI acquisition contingent consideration	280
Balance as of September 30, 2020	$ 2,280

Industrial Seed Innovations A_3

Industrial Seed Innovations Acquisition - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)InstallmentTermshares	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)shares	Sep. 30, 2019USD ($)
Business Acquisition [Line Items]
Revenues	$ 314,000	$ 392,000	$ 904,000	$ 753,000
Existence of option to extend			true
Lease option to extend, description			Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Maximum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract	5 years		5 years
Option to extend lease, term	6 years		6 years
Minimum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract	1 year		1 year
Option to extend lease, term	1 year		1 year
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Purchase price consideration	$ 1,212,000
Cash paid for Acquisition	500,000
Business combination, equity interest issuable, value	432,000
Remaining amount paid in multiple installments	280,000
Revenues	$ 0
Operating leases, term of contract	3 years		3 years
Existence of option to extend	true
Lease option to extend, description	The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.
Number of lease renewal term | Term	3
Option to extend lease, term	3 years		3 years
Industrial Seed Innovations [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs	$ 67,000
Industrial Seed Innovations [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares | shares	132,626
Number of annual installment of common stock shares payable | Installment	2
Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2021 [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626		132,626
Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares	132,626		132,626

Industrial Seed Innovations A_4

Industrial Seed Innovations Acquisition - Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values (Details)	Sep. 30, 2020USD ($)
Business Acquisition [Line Items]
Goodwill	$ 301,000
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Inventory	511
Intangible assets	400
Goodwill	301
Total consideration allocated	$ 1,212

Variable Interest Entity - Addi

Variable Interest Entity - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2012Owner	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Variable Interest Entity [Line Items]
Direct expenses and allocated overhead amount | $		$ 240,000	$ 340,000	$ 454,000	$ 982,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of shareholders owning agricultural investment and development cooperative | Owner	300

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)	Aug. 09, 2019Individual	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)
Schedule Of Equity Method Investments [Line Items]
Restriction percentage of THC at any point during extraction process			0.30%
Value of plants and biomass		$ 1,300,000	$ 1,300,000
Net loss attributable to noncontrolling interest		$ 774,000	$ 1,081,000
Archipelago Ventures Hawaii, LLC [Member] | Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		50.75%	50.75%
Capital contributions		$ 1,927,000	$ 1,927,000
Archipelago Ventures Hawaii, LLC [Member] | Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		49.25%	49.25%
Capital contributions		$ 1,871,000	$ 1,871,000

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)Lease	Apr. 30, 2020Lease	Dec. 31, 2019USD ($)
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendments that provide for additional office space in Davis, CA, and extend the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability
Number of lease amendments | Lease	3	2
Operating Lease, Liability	$ 6,274		$ 2,108
Right of use asset	$ 6,013		$ 1,963
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Operating leases, term of contract	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years
Operating leases, term of contract	5 years
ASU No. 2016-02 [Member]
Lessee Lease Description [Line Items]
Operating Lease, Liability	$ 3,800
Right of use asset	$ 3,800
Premises And Equipment [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	3 years
Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment for additional parcels of land in Molokai, HI, modified the Molokai office space lease to extend the term by 12 months, and entered into new lease agreements for office equipment, collectively resulting in an additional $0.1 million of operating lease liabilities and right of use assets.
Operating Lease, Liability	$ 100
Right of use asset	$ 100
Woodland, CA and Oregon [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend	lease amendment for the land and greenhouse in Woodland, CA, modified the Woodland lease to extend the term by 4 years collectively, and entered into a new lease for the premises and equipment related to the purchase of ISI in Oregon with a three-year term, resulting in an additional $0.5 million of operating lease liabilities and right of use assets.
Operating Lease, Liability	$ 500
Right of use asset	$ 500
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	5 years
Office Space [Member] | Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	12 months
Office Space [Member] | Woodland, CA, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	4 years

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Assets
Operating lease assets	$ 6,013		$ 6,013		$ 1,963
Total leased assets	6,013		6,013		1,963
Liabilities
Current - Operating	700		700		611
Noncurrent - Operating	5,574		5,574		1,497
Total leased liabilities	6,274		6,274		$ 2,108
Lease Cost
Net lease cost	$ 358	$ 209	$ 1,017	$ 627
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	5 years 9 months 18 days		5 years 9 months 18 days		2 years 7 months 6 days
Weighted-average discount rate	6.60%		6.60%		7.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 261	177	$ 745	529
Sublease income	(12)	(13)	(34)	(40)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 109	$ 45	303	$ 138
SG&A Expenses [Member]
Lease Cost
Short term lease cost			$ 3

Private Placement and Registere

Private Placement and Registered Direct Offering - Additional Information (Detail)	Jul. 08, 2020USD ($)$ / sharesshares	May 18, 2020USD ($)$ / sharesshares	Sep. 05, 2019$ / sharesshares	Jun. 12, 2019$ / sharesshares	Jun. 11, 2018$ / sharesshares	Mar. 22, 2018$ / sharesshares	Mar. 19, 2018	Jul. 31, 2020$ / sharesshares	May 31, 2020$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Aug. 13, 2020shares	Jul. 06, 2020USD ($)shares	Jul. 02, 2020shares	May 14, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price | $ / shares											$ 6.31		$ 6.31
Gross proceeds from warrant exercises													$ 9,372,000	$ 5,269,000
Common stock, issued | shares											10,832,203		10,832,203						8,646,149
Common stock value issued											$ 51,000		$ 51,000						$ 49,000
Warrant outstanding | shares											4,450,689		4,450,689
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid													$ 178,000
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares											32,071		32,071
Warrants issued, exercise price | $ / shares											$ 4.969		$ 4.969
Warrants expiration period													5 years 6 months
Offering costs											$ 91,000		$ 91,000
Issuance of placement agent warrants											$ 101,000		101,000
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Aggregate agent fee paid													$ 478,000
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares											69,617		69,617
Warrants issued, exercise price | $ / shares											$ 6.125		$ 6.125
Offering costs											$ 116,000		$ 116,000
Issuance of placement agent warrants													$ 215,000
Warrant, exercisable term													5 years
Warrants [Member] | July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares															32,071
Offering costs											400,000		$ 400,000
Warrants [Member] | July 2020 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares															641,416
Warrants [Member] | May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Offering costs											800,000		800,000
Warrants [Member] | May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares																	69,617
Warrants [Member] | May 2020 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares																	1,392,345
March 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 3,800,000		$ 3,800,000		3,800,000		$ 1,600,000
Additional income (expense) on liabilities													2,200,000	(1,600,000)
Proceeds from issuance of warrants													2,600,000
March 2018 Warrant Liability [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 1,600,000		$ 1,600,000
Stock price | $ / shares											$ 3.81		$ 3.81
March 2018 Warrant Liability [Member] | Measurement Input, Price Volatility [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.51		1.51
March 2018 Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0019		0.0019
June 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										4,500,000		4,500,000		4,500,000				$ 4,000,000
Additional income (expense) on liabilities												(1,900,000)	$ 1,400,000	(1,800,000)
Proceeds from issuance of warrants													6,800,000
June 2018 Warrant Liability [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 4,000,000		$ 4,000,000
Stock price | $ / shares											$ 4		$ 4
June 2018 Warrant Liability [Member] | Measurement Input, Price Volatility [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.40		1.40
June 2018 Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0028		0.0028
June 2019 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 1,600,000	$ 900,000	1,600,000	$ 900,000	1,600,000
Additional income (expense) on liabilities											$ 400,000	(5,300,000)	$ 1,100,000	(4,500,000)
Investors exercised warrants | shares										1,053,745
Warrant outstanding | shares											435,830		435,830
September 2019 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value											$ 1,400,000		$ 1,400,000
Additional income (expense) on liabilities											$ 500,000		1,600,000
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares						1,201,634
Warrant issued, shares of common stock called by warrant | shares						1,282,832
Warrants issued, exercise price | $ / shares						$ 10.7258
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability													$ (682,000)
Offering costs																400,000
Common stock value issued																$ 2,400,000
Warrant outstanding | shares											673,487		673,487
July 2020 Warrant Exercise Transaction [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 2,100,000		$ 2,100,000
Stock price | $ / shares											$ 3.73		$ 3.73
July 2020 Warrant Exercise Transaction [Member] | Measurement Input, Price Volatility [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.26		1.26
July 2020 Warrant Exercise Transaction [Member] | Measurement Input, Risk Free Interest Rate [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0030		0.0030
July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares	641,416							641,416
Warrants issued, exercise price | $ / shares	$ 3.975							$ 3.85
Gross proceeds from warrant exercises	$ 2,600,000
Warrant, exercisable term								5 years 6 months
July 2020 Warrant Exercise Transaction [Member] | Fair Value May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Common stock, issued | shares																641,416
July 2020 Warrant Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares	641,416
Warrants issued, exercise price | $ / shares	$ 3.85
Warrants expiration period	5 years 6 months
Gross proceeds from warrant exercises	$ 2,600,000
Proceeds from issuance of warrants	2,300,000
Offering costs	$ 269,000
June 2018 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares					1,392,345
Warrants issued, exercise price | $ / shares					$ 9.94
Warrants expiration period					5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share | $ / shares					$ 0.125
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability													$ 47,000
Offering costs																		800,000
Common stock value issued																		$ 5,600,000
Warrant outstanding | shares											1,461,962		1,461,962
May 2020 Warrant Exercise Transaction [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Warrants value											$ 4,400,000		$ 4,400,000
Stock price | $ / shares											$ 3.81		$ 3.81
May 2020 Warrant Exercise Transaction [Member] | Measurement Input, Price Volatility [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											1.28		1.28
May 2020 Warrant Exercise Transaction [Member] | Measurement Input, Risk Free Interest Rate [Member] | Black Scholes Merton Model [Member]
Class Of Warrant Or Right [Line Items]
Volatility rate											0.0038		0.0038
May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares		1,392,345							1,392,345
Warrants issued, exercise price | $ / shares		$ 4.90							$ 4.775
Gross proceeds from warrant exercises		$ 6,800,000
Warrant, exercisable term									5 years
May 2020 Warrant Exercise Transaction [Member] | Fair Value May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Common stock, issued | shares																		1,392,345
May 2020 Warrant Transaction [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares		1,392,345
Warrants issued, exercise price | $ / shares		$ 4.775
Warrants expiration period		5 years
Gross proceeds from warrant exercises		$ 6,800,000
Proceeds from issuance of warrants		6,200,000
Offering costs		$ 594,000
June 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares				1,489,575
Warrants issued, exercise price | $ / shares				$ 5
Warrants expiration period				5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share | $ / shares				$ 0.125
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant outstanding | shares											725,356		725,356
September 2019 Purchase Agreement [Member] | Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant | shares			659,414
Warrants issued, exercise price | $ / shares			$ 7.52
Warrants expiration period			5 years 6 months
Class of warrant or right number of securities called by warrants or rights, per share | $ / shares			$ 0.125
March 2018 Private Placement [Member] | March 2018 Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Liabilities marked to market value										$ 3,800,000	$ 800,000	3,800,000	$ 800,000	3,800,000
Additional income (expense) on liabilities											$ 200,000	$ (1,600,000)	$ 2,200,000	$ (1,600,000)
March 2018 Private Placement [Member] | March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares						300,752
Warrant issued, shares of common stock called by warrant | shares						300,752
Warrants issued, exercise price | $ / shares						$ 45.75
Warrants expiration period							5 years
June 2018 Offering [Member] | June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares					1,392,345
Stock price | $ / shares					$ 9.93
June 2018 Offering [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares				1,489,575
Stock price | $ / shares				$ 4.91
September 2019 Offering [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued | shares			1,318,828
Stock price | $ / shares			$ 7.52

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Jun. 26, 2020	May 18, 2020	Apr. 16, 2020	Sep. 30, 2020
Promissory Note [Member] | Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Interest rate			1.00%
Debt instrument, face amount			$ 1,100,000
Debt instrument maturity date			Apr. 16, 2022
Debt instrument, frequency of periodic payment			monthly
Debt instrument, prepayment penalty			$ 0
Debt instrument outstanding amount				$ 1,100,000
Promissory Note [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate		2.50%
Debt instrument maturity date		May 18, 2023
Debt instrument outstanding amount				2,000,000
Line of credit facility initiation date	Jun. 26, 2020
Line of credit facility maximum borrowing capacity	$ 2,000,000
Line of credit facility agreement date		May 18, 2020
Debt instrument interest rate terms		Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Promissory Note [Member[ | MidFirst Bank [Member] | Restricted Cash [Member]
Debt Instrument [Line Items]
Deposit account				$ 2,000,000
Minimum [Member] | Promissory Note [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate		3.25%
Maximum [Member] | Promissory Note [Member[ | MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity		$ 2,000,000
Vehicle Loans [Member]
Debt Instrument [Line Items]
Debt instrument maturity year				2024
Loans				$ 145,000
Vehicle Loans [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate				7.64%
Vehicle Loans [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate				8.00%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Current and Noncurrent Debt (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Lessee Disclosure [Abstract]
Remainder of 2020	$ 126
2021	774
2022	285
2023	2,039
2024	29
Total	$ 3,253

Stock-Based Compensation and _3

Stock-Based Compensation and Warrants - Additional Information (Detail)

Feb. 12, 2020$ / sharesshares

Feb. 03, 2020$ / sharesshares

Mar. 28, 2019shares

May 20, 2015shares

May 14, 2015

Jul. 31, 2020$ / sharesshares

May 31, 2020$ / sharesshares

Feb. 29, 2020$ / sharesshares

Sep. 30, 2019$ / sharesshares

Aug. 31, 2019$ / sharesshares

Jul. 31, 2019$ / sharesshares

Jun. 30, 2019$ / sharesshares

Apr. 30, 2019$ / sharesshares

Sep. 30, 2019$ / sharesshares

Sep. 30, 2020USD ($)$ / sharesshares

Sep. 30, 2019USD ($)$ / sharesshares

Jun. 30, 2019$ / sharesshares

Sep. 30, 2018

Jun. 30, 2019$ / sharesshares

Sep. 30, 2020USD ($)IncentivePlan$ / sharesshares

Sep. 30, 2019USD ($)$ / sharesshares

Jul. 08, 2020$ / sharesshares

May 18, 2020$ / sharesshares

Dec. 31, 2019shares

Sep. 05, 2019$ / sharesshares

Jun. 30, 2014$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of equity incentive plans | IncentivePlan

2

Total number of options outstanding

980,883

980,883

661,701

Unrecognized compensation cost related to unvested stock-based compensation grants | $

$ 1,200,000

$ 1,200,000

Weighted-average remaining recognition period

2 years 8 months 12 days

Options granted

491,494

186,571

Stock-based compensation | $

$ 1,844,000

$ 1,870,000

Number of warrant to purchase common stock issued

4,450,689

4,450,689

Warrants issued, exercise price | $ / shares

$ 6.31

$ 6.31

Service Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.18

Warrant issued, shares of common stock called by warrant

45,154

Warrants vesting period

12 months

Warrant, exercisable term

5 years

Stock compensation expense associated with Warrants, term

1 year

Compensation expense associated with Warrants | $

$ 145,000

$ 56,000

$ 145,000

$ 100,000

Performance Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.18

Warrant issued, shares of common stock called by warrant

100,000

Warrant, exercisable term

5 years

Exercise Price of Warrants Four Point Nine One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants vesting period

12 months

Warrant, exercisable term

2 years

Stock compensation expense associated with Warrants, term

12 months

Compensation expense associated with Warrants | $

9,400

28,200

Exercise Price of Warrants Four Point Seven One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 4.71

Warrant issued, shares of common stock called by warrant

150,000

Warrants vesting period

12 months

Warrant, exercisable term

2 years

Stock compensation expense associated with Warrants, term

12 months

Compensation expense associated with Warrants | $

135,400

406,200

Exercise Price of Service Warrants Four Point Nine One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 2.50

Warrant issued, shares of common stock called by warrant

18,350

Warrant, exercisable term

3 years

Compensation expense associated with Warrants | $

$ 0

$ 36,700

June 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

510,309

510,309

September 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

725,356

725,356

September 2019 Purchase Agreement [Member] | Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 7.52

Warrant issued, shares of common stock called by warrant

659,414

May 2020 Warrant Exercise Transaction [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

1,461,962

1,461,962

May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 4.775

$ 4.90

Warrant issued, shares of common stock called by warrant

1,392,345

1,392,345

Warrant, exercisable term

5 years

July 2020 Warrant Exercise Transaction [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

673,487

673,487

July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 3.85

$ 3.975

Warrant issued, shares of common stock called by warrant

641,416

641,416

Warrant, exercisable term

5 years 6 months

Independent Contractor [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 2.19

Warrant issued, shares of common stock called by warrant

10,000

Independent Contractor [Member] | Exercise Price of Warrants Four Point Nine One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 4.91

Warrant issued, shares of common stock called by warrant

10,000

Two Affiliated Third Parties [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 1.92

Warrant issued, shares of common stock called by warrant

20,000

Placement Agent [Member] | June 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.2938

$ 6.2938

$ 6.2938

Warrant issued, shares of common stock called by warrant

74,479

74,479

74,479

Warrant, exercisable term

5 years

Placement Agent [Member] | September 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 9.4781

$ 9.4781

$ 9.4781

$ 9.4781

Warrant issued, shares of common stock called by warrant

65,942

65,942

65,942

65,942

Warrant, exercisable term

5 years

Placement Agent [Member] | May 2020 Warrant Exercise Transaction [Member] | Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.125

Warrant issued, shares of common stock called by warrant

69,617

Warrant, exercisable term

5 years

Placement Agent [Member] | July 2020 Warrant Exercise Transaction [Member] | Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 4.969

Warrant issued, shares of common stock called by warrant

32,071

Warrant, exercisable term

5 years 6 months

Series D Redeemable Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant issued, shares of common stock called by warrant

63,071

Number of warrants expired

1,759

61,312

Series D Redeemable Convertible Preferred Stock [Member] | Investor [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 363.20

Warrant issued, shares of common stock called by warrant

61,397

Series D Redeemable Convertible Preferred Stock [Member] | Placement Agent [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 268.80

Warrant issued, shares of common stock called by warrant

1,674

2015 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

105,036

105,036

Percentage in payroll deductions to acquire shares of common stock

15.00%

Purchase plan offering period

6 months

Employees are able to purchase company's common stock on first trading day of offering period, percentage

85.00%

Issuance of common stock pursuant to employee stock purchase plan

35,056

Stock-based compensation | $

$ 12,200

$ 4,300

$ 40,500

$ 6,000

Purchase Agreement [Member] | March 2018 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

656,454

656,454

Purchase Agreement [Member] | March 2018 Purchase Agreement [Member] | Purchase Price of $10.7258 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

641,416

641,416

Warrants issued, purchase price of warrants per share | $ / shares

$ 10.7258

$ 10.7258

Purchase Agreement [Member] | March 2018 Purchase Agreement [Member] | Exercise Price of $41.5625 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

15,038

15,038

Warrants issued, exercise price | $ / shares

$ 41.5625

$ 41.5625

Purchase Agreement [Member] | June 2018 Offering [Member] | Exercise Price of $12.568 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

69,617

69,617

Warrants issued, exercise price | $ / shares

$ 12.568

$ 12.568

Purchase Agreement [Member] | June 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 5

$ 5

$ 5

Warrant issued, shares of common stock called by warrant

1,489,575

1,489,575

1,489,575

Warrants issued, purchase price of warrants per share | $ / shares

$ 0.125

$ 0.125

$ 0.125

Warrant, exercisable term

5 years 6 months

Class of warrant or right, issued percentage in connection with common stock sold

100.00%

Investors exercised warrants and purchase shares of common stock

1,053,745

Purchase Agreement [Member] | September 2019 Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 7.52

$ 7.52

$ 7.52

$ 7.52

Warrant issued, shares of common stock called by warrant

659,414

659,414

659,414

659,414

Warrants issued, purchase price of warrants per share | $ / shares

$ 0.125

$ 0.125

$ 0.125

$ 0.125

Warrant, exercisable term

5 years 6 months

Class of warrant or right, issued percentage in connection with common stock sold

50.00%

July 2019 Offering [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants vesting period

12 months

Warrant, exercisable term

2 years

Stock compensation expense associated with Warrants, term

12 months

Compensation expense associated with Warrants | $

$ 2,000

$ 10,000

August 2019 Offering [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant, exercisable term

2 years

Warrants issuance date

Aug. 5, 2019

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant, expiration date

2025-12

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant, expiration date

2021-07

2015 Omnibus Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Terms under the plan

The 2015 Plan became effective in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.

Total number of shares reserved for issuance under plan

154,387

1,047,188

1,047,188

Options vesting period

4 years

2 years

Additional shares authorized for issuance under the plan

120,000

Common stock available for future grant

85,532

85,532

Total number of options outstanding

961,656

961,656

2015 Omnibus Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options exercisable period

10 years

2006 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

10,637

Total number of options outstanding

19,227

19,227

Stock-Based Compensation and _4

Stock-Based Compensation and Warrants - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	661,701
Shares Subject to Outstanding, Options granted	491,494	186,571
Shares Subject to Outstanding, Options Forfeited	(131,849)
Shares Subject to Outstanding, Options Expired	(40,463)
Shares Subject to Outstanding, Ending Balance	980,883
Shares Subject to Outstanding, Vested and expected to vest	965,445
Shares Subject to Outstanding, Exercisable	540,267
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 21.60
Weighted-Average Exercise Price Per Share, Options granted	4.32
Weighted-Average Exercise Price Per Share, Options forfeited	6.39
Weighted-Average Exercise Price Per Share, Options expired	48.57
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	13.87
Weighted Average Exercise Price Per Share, Vested and expected to vest	14.03
Weighted Average Exercise Price Per Share, Exercisable	$ 21.51
Aggregate Intrinsic Value, Outstanding Balance	$ 1		$ 305
Aggregate Intrinsic Value, Vested and expected to vest	$ 1

Stock-Based Compensation and _5

Stock-Based Compensation and Warrants - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 days	6 years 2 months 26 days	6 years 6 months	7 years 1 month 17 days
Expected volatility	230.00%	99.00%	133.00%	99.00%
Risk-free interest rate	0.38%	1.84%	1.03%	2.05%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21.00%
Effective tax rate	(0.10%)	0.00%	(0.10%)	(0.10%)
Uncertain tax positions	$ 0		$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Dec. 31, 2010USD ($)Program	Sep. 30, 2020USD ($)Installmentshares	Sep. 30, 2020USD ($)shares	Dec. 31, 2019USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,280,000	$ 2,280,000	$ 2,000,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000,000				$ 5,000,000
Date of merger and reorganization			Jun. 15, 2005
Restructuring activities, description			As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased | Program	3
Number of development programs | Program	6
Other noncurrent liability		$ 2,000,000	$ 2,000,000
Gain on abandon of technologies			$ 1,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years	3 years
Remaining amount paid in multiple installments		$ 280,000
Industrial Seed Innovations [Member] | Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable | Installment		2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year	1 year
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years	5 years
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2021 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares		132,626	132,626
Maximum [Member] | Industrial Seed Innovations [Member] | Common Stock [Member] | Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone | shares		132,626	132,626

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
Remainder of 2020	$ 500
2021	750
Total	$ 1,250

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	5,431,572	4,861,652	5,431,572	4,861,652
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	980,883	691,001	980,883	691,001
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,450,689	4,170,651	4,450,689	4,170,651

Net Loss per Share - Summary _2

Net Loss per Share - Summary of Computation of Basic and Diluted Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net loss attributable to common stockholders	$ (6,391)	$ (14,187)	$ (13,553)	$ (22,562)
Denominator:
Weighted average number of common shares outstanding	10,719,618	6,942,612	9,570,259	5,596,545
Basic net loss per share attributable to common stockholders:	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)
Numerator:
Net loss attributable to common stockholders	$ (6,391)	$ (14,187)	$ (13,553)	$ (22,562)
Denominator:
Weighted average number of common shares outstanding	10,719,618	6,942,612	9,570,259	5,596,545
Weighted average number of common shares outstanding - diluted	10,719,618	6,942,612	9,570,259	5,596,545
Diluted net loss per share attributable to common stockholders:	$ (0.60)	$ (2.04)	$ (1.42)	$ (4.03)

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	1 Months Ended			3 Months Ended	9 Months Ended
	Apr. 30, 2020USD ($)aLease	Mar. 31, 2020USD ($)a	Feb. 28, 2019USD ($)a	Sep. 30, 2020USD ($)Lease	Sep. 30, 2020USD ($)Lease	Dec. 31, 2019USD ($)
Related Party Transaction [Line Items]
Royalty fees due				$ 29,000	$ 29,000	$ 40,000
Number of lease amendments | Lease	2			3	3
Lease payments				$ 36,000	$ 84,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land | a			10
Operating leases, term of contract			2 years
Rent payments			$ 1,200
Out of pocket costs			126,400
Payments received from contractor			$ 44,000
Amendment [Member] | Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land | a	15	10
Operating leases, term of contract	2 years	2 years
Number of additional properties under lease agreement	two additional 15-acre parcels	two additional 10-acre parcels
Rent payments	$ 1,200	$ 1,200
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due				$ 29,000	$ 29,000	$ 40,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Verdeca LLC [Member] - Bioceres Crop Solutions [Member] - USD ($)	Dec. 12, 2020	Nov. 12, 2020
Master Transaction Agreement [Member] | Forecast [Member]
Subsequent Event [Line Items]
Cash receivable from sale of interest in joint venture	$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture	625,000
Pledge and Security Agreement [Member] | Forecast [Member]
Subsequent Event [Line Items]
Shares of common stock receivable from sale of interest in joint venture	625,000
Subsequent Event [Member] | Master Transaction Agreement [Member]
Subsequent Event [Line Items]
Cash receivable from sale of interest in joint venture		$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture		1,875,000
Additional cash receivable for transaction expenses and fees		$ 1,000,000
Additional cash receivable from sale of interest in joint venture		$ 2,000,000
Sale of interest in joint venture, description of transaction		BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of HB4 soybeans or if China approves the HB4 soybean trait for “food and feed”.
Percentage of royalty payments on net revenues		6.00%
Percentage of wheat sales		25.00%
Restricted period on sale or transfer of common stock		180 days
Subsequent Event [Member] | Maximum [Member] | Master Transaction Agreement [Member]
Subsequent Event [Line Items]
Technology royalty revenue receivable on trait fees, from sale of interest in joint venture		$ 10,000,000